Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Subjects

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavaleukin alfa (Primary)
  • Indications Graft-versus-host disease; Inflammation; Systemic lupus erythematosus; Ulcerative colitis
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Amgen

    • Most Recent Events

    • 11 Oct 2022 Results assessing safety and tolerability of efavaleukin alfa and its effects on expansion of Treg, Tcon, and other immune cells in healthy subjects presented at the 30th United European Gastroenterology Week
    • 18 Jul 2018 New trial record
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top